Tonghua Dongbao Pharma acquired China rights to two diabetes treatments from Adocia of Lyon, France in an agreement worth up to $135 million. Dongbao will have rights to BioChaperone® Combo, a fixed-ratio insulin glargine and insulin lispro combination, plus BioChaperone® Lispro, an ultra-rapid insulin. Adocia’s BioChaperone platform uses polymers, oligomers and small organic compounds to protect proteins from degradation. Dongbao already has a portfolio of diabetes treatments.
Source: China Biotoday